Mandate

Vinge advises Manor Investment S.A. on investment in Rabbalshede Kraft AB (publ)

June 20, 2013

Vinge is advising Manor Investment S.A. in connection with its investment in Rabbalshede Kraft AB (publ). The investment is made through inter alia acquisition of newly issued shares of class B in a private placement, acquisition of 347,500 shares of class A from certain of the current main shareholders, and through acquisition of newly issued shares of class B in a rights issue. Manor is a private industrial company within the renewable energy sector providing long-term development capital to entrepreneurs and industrial projects in Europe aiming for the better use of energy and natural resources. Rabbalshede develops and operates wind power farms in Sweden, with a current portfolio of 26 wind turbines proprietarily managed, 14 turbines under construction and about 350 turbines in the procurement, application or planning phase. Closing of the transactions is subject to certain conditions precedent. Manor is advised by Treïs (www.treispartners.com).

The Vinge team advising Manor includes partner Michael Wigge and associates Peter Sundgren and Louise Markgren (M&A), partner Thomas Sjöberg and associate Johan Cederblad (Real Estate & Environmental), and associate Albert Wållgren (Banking & Finance).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026